Mizuho raised the price target for the AvroBio Inc (NASDAQ:AVRO) stock from “a Buy” to “a Neutral”. The rating was released on December 18, 2023, according to finviz. The research report from Morgan Stanley has downgraded the stock from Overweight to Equal-Weight, with a price target set at $7. The stock was initiated by BTIG Research, who disclosed in a research note on June 15, 2021, to Buy and set the price objective to $23. In their research brief published May 27, 2021, Needham analysts initiated the AvroBio Inc stock to Buy with a price target of $28.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 8.63% within the last five trades and 27.43% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 18.90% in the last 6 months and 16.15% was added to its value over the previous 3 months. AVRO stock is trading at a margin of 16.78%, 18.85% and 8.91% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of the close of trading, AVRO deals in the Healthcare domain. The stock is trading -8.48 percent below its 52-week high and 71.57 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 13.44. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does AvroBio Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $67.78 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for AvroBio Inc (NASDAQ:AVRO) is 2.19. The firm managed a Price-to-Book ratio of 0.76, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 13.41 percent of AvroBio Inc shares are owned by insiders, and 57.42 percent are held by financial institutions. Leonard Braden Michael, the 10% Owner at AvroBio Inc (AVRO) has bought 296,882 shares of firm on May 14 ’24 at a price of $1.30 against the total amount of $0.39 million. In another inside trade, Leonard Braden Michael, 10% Owner of AvroBio Inc (NASDAQ:AVRO) bought 469,753 shares of the firm on May 13 ’24 for a total worth of $0.59 million at a price of $1.25.
